2018 Closer are closer....." for retinopathy of prematurity indication" ONLY...many more indication to come.
"It is our intention to seek licensing partners for the IPLEX development programs. In 2012, we out-licensed the IPLEX technology to Premacure Holdings AB and Premacure AB of Sweden (collectively, Premacure) for retinopathy of prematurity indication. In March 2013, we amended the Premacure License Agreement to provide Premacure with the option to pay us $11.5 million and assume any of our royalty obligations to other parties in exchange for a fully paid license. In March 2013, Shire plc announced that they acquired Premacure. In April 2013 Shire exercised this optionand paid us $11.5 million, and as a result we are not entitled to future royalties from Shire."
Keep this one in memory....we will post it again in October well above 20....I love this guy!
ATS International Conference 2014: NTM Goes Under the Microscope
...The Research meeting was co-sponsored by ATS and NTM Info & Research. NTM Info is pleased to have been able to support and participate in this meeting, the findings of which will be published as a paper in one of the ATS publications later this year, once the committee publishes its notes.
In addition to the NTM Research Agenda Meeting, this year’s conference held in San Diego, CA, featured a prominent booth in the Exhibition Hall by Insmed (the makers of ARIKAYCE™, an inhaled liposomal Amikacin which just completed Phase II clinical trials), as well as numerous conference workshops and a symposium on NTM sponsored by Insmed. The attention-grabbing booth featured an informative video on NTM lung disease playing on TV screens mounted on both sides of the booth, as well as NTMir’s flagship publication, “Insight: A Patient’s Perspective,” and other informational materials. (Click here for pictures of the booth and symposium.)
The Insmed-sponsored symposium conducted in partnership with NTMir, titled “NTM Isn’t Waiting, Neither Should You,” was a resounding success. With initial attendance expected to reach 125 people, the final count was 305 clinicians and researchers who showed up to join an interactive learning-based event. Symposium faculty Dr. Charles Daley, Dr. Kevin Winthrop, Dr. Ken Olivier and Dr. David Griffith posed questions to the audience members, who were able to answer using iPads set up at each table, with the results tabulated in real time and displayed on screens around the room. (Click here for pictures from the symposium.)
Auto Covered today. $29,435 profit...thanks to terry again. Thanks buddy.
No, I set my bids earlier today and have not got there yet. They are going to walk it back down until news so I have security as of this morning too. We know how this is going to work out but market wants to see Breakthrough Design. and they giddy up mode begins. I have not sold but set my buys and got insurance earlier today to make money while the MM play. We need to look at the next 60 days for news...a lot of playing in the meantime.
CF Pa presentation Tuesday, 5/20 8:15 a.m. San Diego Convention Center
No unexpected AEs
Treatment-emergent AEs consistent with underlying CF
Minimally important differences on Respiratory Symptom scale were observed at the end of all cycles with LAI, while only observed after first cycle Tobi.
Improvement on- verses off-treatment with LAI,
Thank you BWD
LOL, I love it....just give him rope and the boy just can't help himself. In all and all....I do hope is safe due to the Wild Fires in that area. Stay safe Terry!....
"It is now clear that Arikayce is a better and safer product than Tobi for CF and should assume the role of primary therapy" Jad this should be in the headlines soon enough.
"compelling data" and now or soon the FDA will look at the data and make a decision. They have been working closes with the FDA and think we will get the go ahead!!!!
pianoman, why is my id in the headline of this post...I must have been missing something...reported....and to the original author of this...."Simple thoughts for simple people." Grow up!
Sentiment: Strong Buy